<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03748095</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A02681-54</org_study_id>
    <secondary_id>2017/384/HP</secondary_id>
    <nct_id>NCT03748095</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetic Modeling to Optimize the Dosage of the Piperacillin / Tazobactam Combination in Patients With Sepsis in Intensive Care</brief_title>
  <acronym>OPT-TAZ</acronym>
  <official_title>Population Pharmacokinetic Modeling to Optimize the Dosage of the Piperacillin / Tazobactam Combination in Patients With Sepsis in Intensive Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Population pharmacokinetic modeling mathematically describes the pharmacokinetics of a drug&#xD;
      and the variables likely to influence it in a &quot;typical&quot; patient population. We propose to&#xD;
      model a Bayesian estimator, taking into account the individual factors that influence&#xD;
      exposure to the piperacillin / tazobactam combination in a target population of sepsis, to&#xD;
      allow for early assessment of serum Piperacillin / Tazobactam concentration profiles.&#xD;
      optimization of dosing regimens. Indeed, pharmacokinetic tools of this type are already&#xD;
      regularly successfully applied for other classes of antibiotics or immunosuppressants whose&#xD;
      therapeutic index is narrow. They reduce the toxic risk and optimize the effectiveness of&#xD;
      these treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">January 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The objective is to develop a Bayesian estimator of the area under the blood concentration curves of the piperacillin / tazobactam combination in resuscitation patients with sepsis.</measure>
    <time_frame>24hours</time_frame>
    <description>The primary endpoint of this study is the ability of the pharmacokinetic model developed to predict the AUC of the piperacillin / tazobactam combination at 24 hours after initiation of antibiotic therapy.</description>
  </primary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Resuscitation Patients With Sepsis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pipéracilline/tazobactam</intervention_name>
    <description>There is not intervention description</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient hospitalized in intensive care for sepsis, involving (i) a suspected or proven&#xD;
        infection; (ii) a systemic inflammatory response; (iii) dysfunction of at least one organ,&#xD;
        according to the international consensus &quot;sepsis-3&quot;&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major patient (age ≥18 years) male or female.&#xD;
&#xD;
          -  Patient hospitalized in intensive care for sepsis, involving (i) a suspected or proven&#xD;
             infection; (ii) a systemic inflammatory response; (iii) dysfunction of at least one&#xD;
             organ, according to the international consensus &quot;sepsis-3&quot;.&#xD;
&#xD;
          -  Patient with an arterial catheter that can be used for blood sampling by the time the&#xD;
             first dose of piperacillin / tazobactam is administered.&#xD;
&#xD;
          -  Patient for whom treatment with piperacillin / tazobactam, alone or in combination&#xD;
             with another antibiotic, is prescribed according to the following modalities (drug&#xD;
             SPC): scheduled antibiotic treatment for at least 48 hours in IV infusion of 4 g of&#xD;
             piperacillin and 0.5 g tazobactam over 3 hours, every 6 hours or every 8 hours.&#xD;
&#xD;
          -  Patient affiliated to a social security scheme.&#xD;
&#xD;
          -  Patient informed and given his non-opposition. If the patient is unable to do so&#xD;
             (emergency situations) the non-opposition will be obtained from the patient's&#xD;
             representative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with piperacillin and / or tazobactam within 7 days prior to evaluation.&#xD;
&#xD;
          -  Patient with a history of allergy to penicillins or β-lactams.&#xD;
&#xD;
          -  Kidney function of Kdigo score = 3 (3 times baseline plasma creatinine or plasma&#xD;
             creatinine ≥ 354μmol / L or extra-renal clearance, or diuresis &lt;0.3ml / kg / h for ≥&#xD;
             24h or anuria for ≥ 12h) to not include patients at very high risk of extra-renal&#xD;
             clearance within 48 hours.&#xD;
&#xD;
          -  Hypersensitivity to the active substances, to any other antibacterial agent of the&#xD;
             penicillin class or to any of the excipients.&#xD;
&#xD;
          -  History of severe allergic reaction to any other β-lactam.&#xD;
&#xD;
          -  Patient being treated with extrarenal treatment.&#xD;
&#xD;
          -  Patient being treated with extracorporeal circulation (ECMO).&#xD;
&#xD;
          -  Hepatic insufficiency patient with Child C. cirrhosis.&#xD;
&#xD;
          -  Patient who refused to participate or refused participation by the representative.&#xD;
&#xD;
          -  Person deprived of liberty by an administrative or judicial decision.&#xD;
&#xD;
          -  Person under tutorship or curatorship.&#xD;
&#xD;
          -  Pregnant or nursing woman.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 16, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>November 16, 2018</last_update_submitted>
  <last_update_submitted_qc>November 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

